Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
Nature|August 30, 2019
Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylationJixiao Niu, Yang Sun, Baoen Chen, et al.Nature|June 20, 2020
Retraction Note: Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylationJixiao Niu, Yang Sun, Baoen Chen, et al.Nature Genetics|January 15, 2013
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumorsJuliann Chmielecki, Aimee M Crago, Mara Rosenberg, et al.Neoplasia (New York, N.Y.)|November 26, 2019
CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3Susana P Egusquiaguirre, Suhu Liu, Isidora Tošić, et al.Molecular Cancer Therapeutics|January 18, 2014
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2Suhu Liu, Sarah R Walker, Erik A Nelson, et al.Science Signaling|January 30, 2014
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypesMichael Xiang, Nicolai J Birkbak, Vida Vafaizadeh, et al.Epigenomics|December 28, 2020
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibitionStephan J Matissek, Weiguo Han, Mona Karbalivand, et al.Blood|January 15, 2011
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsErik A Nelson, Sarah R Walker, Ellen Weisberg, et al.Genes & Cancer|December 25, 2012
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.Oncogenesis|February 24, 2019
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenograftsChun-Hau Chen, Swati Bhasin, Prateek Khanna, et al.Pageof 4